All News
Filter News
Found 808,690 articles
-
Catalys Pacific Launches in Japan to Advance Early-Stage Life Sciences Innovation by Creating and Investing in Global Companies
6/17/2019
Catalys Pacific, a new venture capital firm in Japan built by a global team seasoned in life sciences investing, announces the launch of its first fund.
-
Neurana Pharmaceuticals Announces Completion of Enrollment in the Phase 2 Study of Tolperisone in Acute Muscle Spasms of the Back
6/17/2019
Neurana Pharmaceuticals announced that it has completed enrollment in the "STAR Study," a Phase 2 dose ranging study of tolperisone in acute muscle spasms of the back in over 400 patients.
-
University of Minnesota Releases 'MN-Washburn' Wheat
6/17/2019
New disease-resistant wheat named after the Washburn A Mill
-
NuVasive Expands Advanced Materials Science™ Portfolio with Launch of Porous Titanium Spine Implant for Transforaminal Lumbar Interbody Fusion
6/17/2019
NuVasive, Inc. announced the commercial launch of Modulus® TLIF-O, a porous titanium spine implant engineered for the transforaminal lumbar interbody fusion procedure.
-
Global "5 For The Fight Month" Campaign Culminates in $1M Raised for Cancer Research
6/17/2019
Worldwide campaign activated individuals during the month of May, including a virtual 5K with over 1,200 participants in more than 25 countries and 30 cities [17-June-2019] SALT LAKE CITY and SEATTLE , June 17, 2019 /PRNewswire/ -- In the month of May, 5 For The Fight , a global movement inviting everyone to give $5 for the fight against cancer, raised $1 mill
-
Ortho Regenerative Technologies Announces Changes in Executive Leadership
6/17/2019
Bio-Pharma veteran Claude LeDuc to replace Dr. Brent Norton as President and Chief Executive Officer
-
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
6/17/2019
Arena Pharmaceuticals, Inc. announced that the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis.
-
Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
6/17/2019
Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation
-
Federal, State and Local Officials Join AMPAC Fine Chemicals in Celebrating Re-Opening of Facility Operations in Petersburg, VA
6/17/2019
AFC will grow its pharmaceutical manufacturing capabilities with advanced technology and refreshed infrastructure, bringing more than 110 new jobs to Petersburg over the next few years
-
Flex Pharma Announces Overwhelming Support to Date for the Proposed Merger with Salarius Pharmaceuticals but More Votes are Needed to Complete the Merger
6/17/2019
Special Meeting of Stockholders Adjourned Until July 12, 2019
-
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
6/16/2019
Oncopeptides AB announced updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial.
-
Autism Community Ventures and Dr. Maureen Dunne Announce Transition2Success Scholarship Winners for Teens With Autism
6/16/2019
Autism Community Ventures, a nonprofit organization dedicated to helping people on the autism spectrum successfully integrate into 21st-century careers, is proud to announce that the inaugural round of transition scholarships for its Transition2Success Project have been awarded.
-
MiMedx Continues to Fight against Holding 2019 Annual Meeting
6/16/2019
MiMedx Shareholder Group issued the following statement to fellow shareholders of MiMedx Group, Inc.:
-
Forty Seven, Inc. Announces Updated Data from Phase 1b/2 Clinical Trial of 5F9 in Combination with Rituximab in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma
6/15/2019
Durable Responses Observed in DLBCL and Indolent Lymphoma; Median Duration of Response Not Yet Reached
-
ROADSTER-2 Demonstrates Compelling Patient Outcomes with Strong Safety Profile
6/15/2019
Final Results Presented in Late-Breaking Session at Society for Vascular Surgery 2019 Vascular Annual Meeting
-
Delays on Ebola = Death
6/15/2019
As Ebola spreads to Uganda, WHO continues to delay declaring an international emergency in the face of a devastating crisis—the WHO, UN, AU and DRC must do more to end the current outbreak!
-
Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
6/15/2019
Incyte announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo.
-
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
6/15/2019
Blueprint Medicines Corporation, announced updated data from the ongoing, registration-enabling EXPLORER trial of avapritinib in patients with systemic mastocytosis.
-
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
6/15/2019
Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)
-
CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia
6/15/2019
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine